1 Min Read
* Has resubmitted to U.S. FDA NDA for its investigational candidate Yosprala Source text for Eikon: Further company coverage: (Bengaluru Newsroom +91 80 6749-1130; within U.S. +1 646 223 8780)
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.